The objectives of the CPA | ||||||
---|---|---|---|---|---|---|
1st CPA  1990-1995 | 2nd CPA 1995-2000 | 3rd CPA 2000–2005 | 4th CPA 2005–2010 | 5th CPA 2010–2015 | 6th CPAa 2015–2020 | 7th CPAa 2020–2025 |
1. Access and affordabilityb | ||||||
 |  | Consumer access to quality ph’cy services Expansion of prof. roles including medicine reviews | Location rules ensure access to PBS medicines and benefit Aust consumers | Patient-focused care All have access to the PBS | Access to new PBS medicines | Access to patient-focused programs |
2. Effective healthcare treatment and careb (outcomes) | ||||||
 |  | Co-ordinated multi-disciplinary services | Optimise effectiveness and value. Efficient and effective outcomes Improve h/care outcomes via evidence-based professional programs | Health benefits of evidence-based programs |  |  |
3. Longer-term sustainabilityb (incl. viability) | ||||||
 |  | Stable, predictable environment Network of well-distributed, viable and accessible CPs Financial stability for C’wth and PGA | Fair price paid to pharmacists by Commonwealth for PBS | Fair price paid to pharmacists by Commonwealth for PBS Sustainable PBS | Cost-effective and sustainable PBS |  |
4. Economic efficiencyb | ||||||
 |  | Well developed, effective, efficient and well-distributed CP network | Funds properly expended—efficient and accountable Maximise value to taxpayers Effective and efficient CP network Improved efficiency through competition between ph’cies | Efficient PBS Efficiency through competition |  |  |
5. Quality of careb | ||||||
 |  | Quality patient care outcomes Quality personalised ph’cy service Intro. of qual. standards | Quality pharmacy service to consumers |  | Quality Use of Medicines (QUM) | Support for QUM |
6. Public interest accountabilityb (and transparency) | ||||||
 |  |  | Transparent and accountable in exp of funds Accountability efficiency and transparency in admin and delivery Meets standards of accountability | Accountability and transparency in admin and delivery of programs Proper expenditure of funds |  | Transparent and appropriate out-of-pocket costs |
7. Democratic participation and openness of decision-makingb | ||||||
 |  |  |  |  |  | Involvement of a broader more inclusive set of stakeholders |
8. Social equity and social justiceb | ||||||
 | Maintain services in remote and isolated areas | Access for rural and remote, and Indigenous people | Programs target areas of need Improvements for indigenous people | Target areas of need incl. indigenous people |  |  |
9. Other criteria (not Hancock) | ||||||
A more efficient CP structure … benefit to both parties | Maintain benefit of restructuring Not increase the number of pharmacies | Extended cooperation evident in CPA 1 and 2 | Co-operative relationship between C’wth and PGA | Co-operative relationship between C’wth and PGA |  | Cooperation between signatories and a broader set of stakeholders |
 |  | Stable and viable CP sector CP services take account of Competition Policy IT improved med management | Stable and viable CP sector. Location rules ensure commercially viable and sustainable network and increase flexibility to respond to need | Sustainable and viable CP sector, flexible to respond to needs. Clear roles for C’wth and PGA |  | Predictable remuneration to support CP network |